1. Syndecan-4: major player or innocent bystander of the endothelial glycocalyx?
- Author
-
Kevin J. McCarthy
- Subjects
0301 basic medicine ,matrix metalloproteinase ,030232 urology & nephrology ,Biology ,Matrix metalloproteinase ,Glycocalyx ,Article ,Syndecan 1 ,03 medical and health sciences ,0302 clinical medicine ,Glomerular Filtration Barrier ,Bystander effect ,Diabetes Mellitus ,glomerular endothelial glycocalyx ,Humans ,Diabetic Nephropathies ,chemistry.chemical_classification ,diabetes ,urogenital system ,Endothelial glycocalyx ,Matrix Metalloproteinases ,Cell biology ,carbohydrates (lipids) ,Endothelial stem cell ,030104 developmental biology ,chemistry ,Nephrology ,Syndecan-4 ,Glycoprotein ,Function (biology) - Abstract
The endothelial glycocalyx is a key component of the glomerular filtration barrier. We have shown that matrix metalloproteinase (MMP)-mediated syndecan 4 shedding is a mechanism of glomerular endothelial glycocalyx damage in vitro, resulting in increased albumin permeability. Here we sought to determine whether this mechanism is important in early diabetic kidney disease, by studying streptozotocin-induced type 1 diabetes in DBA2/J mice. Diabetic mice were albuminuric, had increased glomerular albumin permeability and endothelial glycocalyx damage. Syndecan 4 mRNA expression was found to be upregulated in isolated glomeruli and in flow cytometry-sorted glomerular endothelial cells. In contrast, glomerular endothelial luminal surface syndecan 4 and Marasmium oreades agglutinin lectin labelling measurements were reduced in the diabetic mice. Similarly, syndecan 4 protein expression was significantly decreased in isolated glomeruli but increased in plasma and urine, suggesting syndecan 4 shedding. Mmp-2, 9 and 14 mRNA expression were upregulated in isolated glomeruli, suggesting a possible mechanism of glycocalyx damage and albuminuria. We therefore characterised in detail the activity of MMP-2 and 9 and found significant increases in kidney cortex, plasma and urine. Treatment with MMP-2/9 inhibitor I for 21 days, started six weeks after diabetes induction, restored endothelial glycocalyx depth and coverage and attenuated diabetes-induced albuminuria and reduced glomerular albumin permeability. MMP inhibitor treatment significantly attenuated glomerular endothelial and plasma syndecan 4 shedding and inhibited plasma MMP activity. Thus, our studies confirm the importance of MMPs in endothelial glycocalyx damage and albuminuria in early diabetes and demonstrate that this pathway is amenable to therapeutic intervention. Hence, treatments targeted at glycocalyx protection by MMP inhibition may be of benefit in diabetic kidney disease., Graphical abstract
- Published
- 2020